thalidomide has been researched along with Epidermolysis Bullosa Simplex in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Epidermolysis Bullosa Simplex: A form of epidermolysis bullosa characterized by serous bullae that heal without scarring. Mutations in the genes that encode KERATIN-5 and KERATIN-14 have been associated with several subtypes of epidermolysis bullosa simplex.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castela, E | 1 |
| Tulic, MK | 1 |
| Rozières, A | 1 |
| Bourrat, E | 1 |
| Nicolas, JF | 1 |
| Kanitakis, J | 1 |
| Vabres, P | 1 |
| Bessis, D | 1 |
| Mazereeuw, J | 1 |
| Morice-Picard, F | 1 |
| Baty, D | 1 |
| Berard, F | 1 |
| Lacour, JP | 1 |
| Passeron, T | 1 |
| Chiaverini, C | 1 |
| Mellerio, JE | 1 |
1 trial available for thalidomide and Epidermolysis Bullosa Simplex
| Article | Year |
|---|---|
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Epidermolysis Bullosa Simpl | 2019 |
1 other study available for thalidomide and Epidermolysis Bullosa Simplex
| Article | Year |
|---|---|
Potential therapeutic targeting of inflammation in epidermolysis bullosa simplex.
Topics: Epidermolysis Bullosa Simplex; Humans; Inflammation; Mutation; Thalidomide | 2019 |